With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the presentations to look for.
This year expect 15 oral and poster presentations covering brentuximab vedotin (Adcetris®, Seattle Genetics/Takeda), an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas.
The drug, which is one of five approved and commercially available antibody-drug comjugates, is being evaluated globally as the foundation of care for CD30-expressing lymphomas in more than 70 corporate- and investigator-sponsored clinical trials.
“At this year’s ASH meeting, [brentuximab vedotin] … will be featured in … updated analyses from ECHELON-1 and ECHELON-2 phase III frontline trials,” noted Roger Dansey, MD, Chief Medical Officer at Seattle Genetics.
“We are encouraged by the ECHELON-1 update supporting a sustained progression-free survival benefit for brentuximab vedotin in combination with AVD when compared to ABVD in advanced classical Hodgkin lymphoma and additional analyses from trials evaluating ADCETRIS in combination with nivolumab. We continue to invest in our ADCETRIS clinical development program with the goal of improving outcomes for patients,” Dansey concluded
|Title||Presented||Abstract||Session||Date /Time Location|
|Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085||P. Rubinstein, Rush University Medical Center, Chicago, Ill.||130||Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma||Saturday, December 7, 10:15 a.m. ET|
Tangerine 2 (WF2)
|Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study||A. Stamatoullas, Departement d’Hematologie, Centre Henry Becquerel, Rouen, France||132||Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma||Saturday, December 7, 10:45 a.m. ET|
|Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥ 60 Years||C. Yasenchak, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, Oregon.||237||Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma||Saturday, December 7, 2:30 p.m. ET|
|Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma: Long-term Follow-up Results from the Single-arm Phase 1/2 Study||A. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, N.Y.||238||Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma||Saturday, December 7, 2:45 p.m. ET|
|Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin as Pre-Transplant Salvage for Hodgkin Lymphoma||1555||Poster Presentation||Saturday, December 7, 5:30-7:30 p.m. ET|
|A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) as Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas||W. Pearse, Loyola University Medical Center, Maywood, Ill.||351||Oral presentation Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy||Sunday, December 8, 8:00 a.m. ET|
|An Exploratory Analysis of Brentuximab Vedotin plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant||K. Savage, British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia and the Department of Medical Oncology, Vancouver, B.C., Canada||464||Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Novel Therapies in Peripheral T-cell Lymphomas||Sunday, December 8, 12:15 p.m. ET|
Valencia D (W415D)
|A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma||2834||Poster Presentation||Sunday, December 8, 6:00-8:00 p.m. ET|
|Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma||2836||Poster Presentation||Sunday, December 8, 6:00-8:00 p.m. ET |
|Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above||2852||Poster Presentation||Sunday, December 8, 6:00-8:00 p.m. ET|
|Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom||3482||Poster Presentation||Sunday, December 8, 6:00-8:00 p.m. ET|
|Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma (PTCL)||3492||Poster Presentation||Sunday, December 8, 6:00-8:00 p.m. ET|
|Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Expressing Peripheral T-cell Lymphomas||4023||Poster Presentation||Monday, December 9, 6:00-8:00 p.m. ET|
|Brentuximab Vedotin with Chemotherapy for Stage III/IV Classical Hodgkin Lymphoma (cHL): Four-Year Update of the ECHELON-1 Study||4026||Poster Presentation||Monday, December 9, 6:00-8:00 p.m. ET|
|A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or other CD30 Expressing PTCL||4054||Poster Presentation||Monday, December 9, 6:00-8:00 p.m. ET|